BioCentury
ARTICLE | Emerging Company Profile

Dialing down dynamin

How Dynacure’s antisense therapy could treat all forms of CNM

May 13, 2017 1:10 AM UTC

Dynacure S.A.S. is developing an antisense oligonucleotide against DNM2 that could treat all three subtypes of centronuclear myopathy, two of which are not covered by industry’s pipeline.

Centronuclear myopathy (CNM) is a group of rare congenital muscle disorders characterized by muscle weakness, hypotonia and muscle atrophy, frequently resulting in early death...

BCIQ Company Profiles

Dynacure S.A.S.

BCIQ Target Profiles

Dynamin 2 (DNM2)